Ying S C, Gewurz H, Kinoshita C M, Potempa L A, Siegel J N
Department of Immunology/Microbiology, Rush Medical College, Chicago, IL 60612.
J Immunol. 1989 Jul 1;143(1):221-8.
Multiple mAb to human C-reactive protein (CRP) were prepared which reacted preferentially with either native CRP, modified CRP (expressing "neo-CRP" determinants) or both forms of the molecule. These mAb were divided into four groups according to their binding characteristics to various CRP preparations and CRP peptides by using a combination of ELISA, dot blot, and Western blot assays; they were further characterized based upon their reactivity with CRP in the presence of calcium and inhibition by phosphorylcholine. The first group consisted of mAb that reacted only with native CRP, and served to define four distinct native CRP epitopes. The second group consisted of mAb that reacted with native CRP and also with CRP modified by direct immobilization on polystyrene plates, urea-chelation or SDS treatment in the absence of calcium, thus identifying a fifth native CRP epitope; these mAb displayed significantly greater reactivity with native than with modified CRP. The third group included mAb that reacted only with modified CRP and with the larger amino-terminal fragment (residues 1-146) of pronase-cleaved CRP. The fourth group included mAb that reacted only with modified CRP and with the smaller carboxyl-terminal fragment (residues 147-206) of pronase-cleaved CRP; most of these antibodies also reacted with the carboxyl-terminal octapeptide (residues 199-206) of CRP. These experiments have identified mAb that react preferentially with distinct conformational and sequence-determined epitopes of native and modified forms of the CRP molecule, respectively; provide partial identification of the epitopes with which they interact; point to the presence of at least five epitopes on native CRP and at least three epitopes on modified CRP; and provide antibodies suitable for identification and quantitation of native and modified forms of CRP. The mAb directed against neo-CRP epitopes may help identify the presence of this pentraxin and antigenically-related proteins at previously unappreciated sites.
制备了多种针对人C反应蛋白(CRP)的单克隆抗体(mAb),这些抗体优先与天然CRP、修饰的CRP(表达“新CRP”决定簇)或该分子的两种形式发生反应。通过酶联免疫吸附测定(ELISA)、斑点印迹和蛋白质印迹分析相结合的方法,根据这些mAb与各种CRP制剂和CRP肽的结合特性,将它们分为四组;基于它们在有钙存在的情况下与CRP的反应性以及被磷酰胆碱抑制的情况,对它们进行了进一步表征。第一组由仅与天然CRP反应的mAb组成,用于确定四个不同的天然CRP表位。第二组由与天然CRP反应,也与通过直接固定在聚苯乙烯板上、尿素螯合或在无钙情况下进行十二烷基硫酸钠(SDS)处理而修饰的CRP反应的mAb组成,从而确定了第五个天然CRP表位;这些mAb与天然CRP的反应性明显高于与修饰CRP的反应性。第三组包括仅与修饰的CRP以及链霉蛋白酶切割的CRP的较大氨基末端片段(第1 - 146位氨基酸残基)反应的mAb。第四组包括仅与修饰的CRP以及链霉蛋白酶切割的CRP的较小羧基末端片段(第147 - 206位氨基酸残基)反应的mAb;这些抗体中的大多数也与CRP的羧基末端八肽(第199 - 206位氨基酸残基)反应。这些实验鉴定出了分别优先与CRP分子天然形式和修饰形式的不同构象和序列决定表位反应的mAb;对它们相互作用的表位进行了部分鉴定;指出天然CRP上至少存在五个表位,修饰CRP上至少存在三个表位;并提供了适用于鉴定和定量天然和修饰形式CRP的抗体。针对新CRP表位的mAb可能有助于在以前未被认识的位点鉴定这种五聚体蛋白和抗原相关蛋白的存在。